Telmo Eduardo Salas Joya
Telmo Eduardo Salas Joya has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Leonardo Lanzee Mendoza Jiménez
Investigador Independiente
3 shared publications - Oscar Santiago Palomeque Teran
Unión Cementera Nacional – UCEM, Azogues, Ecuador
2 shared publications - Arnulfo Pazos Rodriguez
Investigador Independiente, México
1 shared publication - Evelyn Ileana Reyes Yagual
Hospital Básico Virgen del Cisne, Salinas – Santa Elena – Ecuador
1 shared publication - Israel Arellano González
Investigador independiente, Ciudad de México, México
1 shared publication - Jeniffer Paola Tonato Alava
Investigador independiente, Salcedo, Ecuador
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 14-30
SÍNDROME CARDIOVASCULAR–RIÑÓN–METABOLISMO (CKM): AVANCES EN LA PREVENCIÓN Y EL MANEJO INTEGRAL BASADOS EN EVIDENCIA CIENTÍFICA
The cardiovascular-kidney-metabolic (CKM) syndrome is a comprehensive clinical framework proposed in 2023 by the American Heart Association. This approach describes how the pathophysiological interconnections between adipose tissue accumulation or dysfunction, metabolic risk factors, chronic kidney damage, and cardiac conditions interact. The purpose of this systematic review was to summarize the scientific literature published from 2021 to 2026 on advances in the comprehensive management and prevention of CKM. To achieve this, we conducted an exhaustive search of databases such as PubMed/MEDLINE, Embase, the Cochrane Library, Scopus, and Web of Science, following the criteria of the PRISMA 2020 guidelines. We evaluated clinical guidelines, expert consensus statements, randomized clinical trials, meta-analyses, and key observational studies. Classifying this condition into five stages (0 through 4) helps stratify risk and guides clinical intervention from the earliest stages. In turn, the PREVENT assessment tools facilitate the calculation of 10- and 30-year cardiovascular events by integrating renal and metabolic markers. From a therapeutic perspective, treatment options with cardiorenal benefits particularly SGLT2 inhibitors and GLP-1 receptor agonists have been shown to significantly reduce serious cardiovascular outcomes, the progression of kidney failure, and overall mortality. In the context of Latin America and Ecuador, the high prevalence of obesity, type 2 diabetes, and hypertension, coupled with inequities in access to healthcare, further complicates the burden of disease. In conclusion, implementing a multidisciplinary strategy focused on healthy habits, close monitoring of key indicators, and early prescription of drugs with multiorgan protection is the most effective approach to slowing the progression of CKM and even reversing its stages.
- 16 September 2026
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 14-30
Open AccessSÍNDROME CARDIOVASCULAR–RIÑÓN–METABOLISMO (CKM): AVANCES EN LA PREVENCIÓN Y EL MANEJO INTEGRAL BASADOS EN EVIDENCIA CIENTÍFICA
The cardiovascular-kidney-metabolic (CKM) syndrome is a comprehensive clinical framework proposed in 2023 by the American Heart Association. This approach describes how the pathophysiological interconnections between adipose tissue accumulation or dysfunction, metabolic risk factors, chronic kidney damage, and cardiac conditions interact. The purpose of this systematic review was to summarize the scientific literature published from 2021 to 2026 on advances in the comprehensive management and prevention of CKM. To achieve this, we conducted an exhaustive search of databases such as PubMed/MEDLINE, Embase, the Cochrane Library, Scopus, and Web of Science, following the criteria of the PRISMA 2020 guidelines. We evaluated clinical guidelines, expert consensus statements, randomized clinical trials, meta-analyses, and key observational studies. Classifying this condition into five stages (0 through 4) helps stratify risk and guides clinical intervention from the earliest stages. In turn, the PREVENT assessment tools facilitate the calculation of 10- and 30-year cardiovascular events by integrating renal and metabolic markers. From a therapeutic perspective, treatment options with cardiorenal benefits particularly SGLT2 inhibitors and GLP-1 receptor agonists have been shown to significantly reduce serious cardiovascular outcomes, the progression of kidney failure, and overall mortality. In the context of Latin America and Ecuador, the high prevalence of obesity, type 2 diabetes, and hypertension, coupled with inequities in access to healthcare, further complicates the burden of disease. In conclusion, implementing a multidisciplinary strategy focused on healthy habits, close monitoring of key indicators, and early prescription of drugs with multiorgan protection is the most effective approach to slowing the progression of CKM and even reversing its stages.
- Open Access
- 16 September 2026
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 57-70
INTELIGENCIA ARTIFICIAL PARA EL CRIBADO DE RETINOPATÍA DIABÉTICA: PRECISIÓN DIAGNÓSTICA, IMPLEMENTACIÓN EN ENTORNOS REALES Y DESAFÍOS ÉTICOS
Diabetic retinopathy (DR) is the leading cause of preventable blindness among working-age adults, and its prevalence is increasing in line with the global spread of diabetes mellitus. Objective: To analyze the scientific evidence published from 2016 to 2026 regarding the diagnostic accuracy of artificial intelligence (AI) for DR screening, its application in real-world clinical practice, and the ethics of its use. A systematic narrative literature review was conducted according to the PRISMA 2020 guidelines, involving a search of indexed databases (PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library) for primary studies, systematic reviews, and meta-analyses published in high-impact journals. Deep learning algorithms achieve sensitivities and specificities exceeding 90% in the detection of referable PR under rigorous laboratory conditions; however, these algorithms face limitations in their diagnostic performance in external populations, particularly in low- and middle-income countries. Studies on the implementation of AI within national screening programs document increases in coverage and reductions in costs, although gaps in generalizability still persist due to issues with the representativeness of training datasets. From an ethical perspective, we identify risks of algorithmic bias, equity gaps, issues of clinical accountability, and informed consent. AI is viewed as a tool with the potential to increase access to RD screening, although its use requires rigorous external studies to validate its performance, the creation of clear regulatory frameworks, and the implementation of strategies to mitigate bias.
- 16 September 2026
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 57-70
Open AccessINTELIGENCIA ARTIFICIAL PARA EL CRIBADO DE RETINOPATÍA DIABÉTICA: PRECISIÓN DIAGNÓSTICA, IMPLEMENTACIÓN EN ENTORNOS REALES Y DESAFÍOS ÉTICOS
Diabetic retinopathy (DR) is the leading cause of preventable blindness among working-age adults, and its prevalence is increasing in line with the global spread of diabetes mellitus. Objective: To analyze the scientific evidence published from 2016 to 2026 regarding the diagnostic accuracy of artificial intelligence (AI) for DR screening, its application in real-world clinical practice, and the ethics of its use. A systematic narrative literature review was conducted according to the PRISMA 2020 guidelines, involving a search of indexed databases (PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library) for primary studies, systematic reviews, and meta-analyses published in high-impact journals. Deep learning algorithms achieve sensitivities and specificities exceeding 90% in the detection of referable PR under rigorous laboratory conditions; however, these algorithms face limitations in their diagnostic performance in external populations, particularly in low- and middle-income countries. Studies on the implementation of AI within national screening programs document increases in coverage and reductions in costs, although gaps in generalizability still persist due to issues with the representativeness of training datasets. From an ethical perspective, we identify risks of algorithmic bias, equity gaps, issues of clinical accountability, and informed consent. AI is viewed as a tool with the potential to increase access to RD screening, although its use requires rigorous external studies to validate its performance, the creation of clear regulatory frameworks, and the implementation of strategies to mitigate bias.
- Open Access
- 16 September 2026
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 101-117
RESISTENCIA A LA INSULINA EN LA DIABETES MELLITUS TIPO 2 Y SU PAPEL EN LA PROGRESIÓN DE LA ENFERMEDAD RENAL CRÓNICA Y LAS COMPLICACIONES CARDIOVASCULARES: UNA REVISIÓN NARRATIVA CRÍTICA CON BÚSQUEDA ESTRUCTURADA
Type 2 diabetes is a global health problem whose complications—such as kidney and heart disease—contribute significantly to morbidity and mortality. Insulin resistance is a key factor in type 2 diabetes. For a long time, this resistance was thought to affect only blood glucose control. However, recent research has begun to explore its possible role as a link between kidney and vascular damage. The aim of this review was to analyze the available evidence on how insulin resistance relates to the progression of chronic kidney disease and cardiovascular complications in adults with type 2 diabetes. A literature search was conducted in databases including PubMed, Scopus, Web of Science, ScienceDirect, and Cochrane Library, covering publications from January 2020 to August 2026. Observational studies, systematic reviews, clinical trials, and guidelines were included. The studies examined insulin resistance in relation to renal outcomes such as albuminuria, reduction in glomerular filtration rate, and end-stage renal disease, as well as its connection to cardiovascular outcomes including major adverse events and heart failure. The results show that insulin resistance is associated with the presence of albumin in urine and worse renal function, likely due to mechanisms such as hyperfiltration, inflammation, oxidative stress, and lipotoxicity. Furthermore, a clear connection exists between insulin resistance and atherosclerosis, arterial damage, and cardiac problems. However, there is limited direct evidence demonstrating how insulin resistance leads to the initiation of hemodialysis. Certain medications, such as SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone, offer benefits beyond glycemic control. The review concludes that the evidence supports a clear and logical relationship between insulin resistance, kidney damage, and cardiovascular risk. Nevertheless, heterogeneity between studies and the predominantly observational nature of the evidence limit the ability to establish direct causal relationships.
- 16 September 2026
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 101-117
Open AccessRESISTENCIA A LA INSULINA EN LA DIABETES MELLITUS TIPO 2 Y SU PAPEL EN LA PROGRESIÓN DE LA ENFERMEDAD RENAL CRÓNICA Y LAS COMPLICACIONES CARDIOVASCULARES: UNA REVISIÓN NARRATIVA CRÍTICA CON BÚSQUEDA ESTRUCTURADA
Type 2 diabetes is a global health problem whose complications—such as kidney and heart disease—contribute significantly to morbidity and mortality. Insulin resistance is a key factor in type 2 diabetes. For a long time, this resistance was thought to affect only blood glucose control. However, recent research has begun to explore its possible role as a link between kidney and vascular damage. The aim of this review was to analyze the available evidence on how insulin resistance relates to the progression of chronic kidney disease and cardiovascular complications in adults with type 2 diabetes. A literature search was conducted in databases including PubMed, Scopus, Web of Science, ScienceDirect, and Cochrane Library, covering publications from January 2020 to August 2026. Observational studies, systematic reviews, clinical trials, and guidelines were included. The studies examined insulin resistance in relation to renal outcomes such as albuminuria, reduction in glomerular filtration rate, and end-stage renal disease, as well as its connection to cardiovascular outcomes including major adverse events and heart failure. The results show that insulin resistance is associated with the presence of albumin in urine and worse renal function, likely due to mechanisms such as hyperfiltration, inflammation, oxidative stress, and lipotoxicity. Furthermore, a clear connection exists between insulin resistance and atherosclerosis, arterial damage, and cardiac problems. However, there is limited direct evidence demonstrating how insulin resistance leads to the initiation of hemodialysis. Certain medications, such as SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone, offer benefits beyond glycemic control. The review concludes that the evidence supports a clear and logical relationship between insulin resistance, kidney damage, and cardiovascular risk. Nevertheless, heterogeneity between studies and the predominantly observational nature of the evidence limit the ability to establish direct causal relationships.
- Open Access
- 5 August 2026
- Published by InvestiGO in Revista Politécnica de la Ciencia
- Vol. 4 (9) , 158-177
DIABETES MELLITUS TIPO 2 Y ENFERMEDAD RENAL CRÓNICA: FACTORES ASOCIADOS Y ESTRATEGIAS DE PREVENCIÓN BASADAS EN LA EVIDENCIA
La diabetes mellitus tipo 2 (DM2) representa una de las principales enfermedades crónicas no transmisibles y constituye un importante problema de salud pública debido a su elevadísima prevalencia y a sus complicaciones, entre ellas la enfermedad renal crónica (ERC), una de las principales causas de la insuficiencia renal terminal. La variabilidad de la evidencia sobre los factores asociados y las estrategias preventivas justifican la necesidad de sintetizar el conocimiento existente. El objetivo fue analizar los factores asociados entre la DM2 y la ERC y las estrategias de prevención sustentadas en la evidencia científica. Se realizó una revisión bibliográfica descriptiva, analítica y documental sustentada en las directrices PRISMA 2020. El proceso de búsqueda se realizó en las bases de datos PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, SpringerLink, Wiley Online Library y Cochrane Library, así como en guías internacionales. En los resultados se encontro como principales factores asociados el mal control glucémico, la hipertensión arterial, la obesidad, la dislipidemia, la edad avanzada y los inadecuados estilos vida. También se rescataron el control metabólico integral, las modificaciones de los estilos de vida, el tamizaje periódico de la función renal y el uso de fármacos nefroprotectores por sus beneficios clínicos. En conclusión, la prevención precoz y el abordaje multidisciplinario logran retrasar la progresión de la ERC y mejoran el pronóstico de los pacientes con DM2.
- 5 August 2026
- Published by InvestiGO in Revista Politécnica de la Ciencia
- Vol. 4 (9) , 158-177
Open AccessDIABETES MELLITUS TIPO 2 Y ENFERMEDAD RENAL CRÓNICA: FACTORES ASOCIADOS Y ESTRATEGIAS DE PREVENCIÓN BASADAS EN LA EVIDENCIA
La diabetes mellitus tipo 2 (DM2) representa una de las principales enfermedades crónicas no transmisibles y constituye un importante problema de salud pública debido a su elevadísima prevalencia y a sus complicaciones, entre ellas la enfermedad renal crónica (ERC), una de las principales causas de la insuficiencia renal terminal. La variabilidad de la evidencia sobre los factores asociados y las estrategias preventivas justifican la necesidad de sintetizar el conocimiento existente. El objetivo fue analizar los factores asociados entre la DM2 y la ERC y las estrategias de prevención sustentadas en la evidencia científica. Se realizó una revisión bibliográfica descriptiva, analítica y documental sustentada en las directrices PRISMA 2020. El proceso de búsqueda se realizó en las bases de datos PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, SpringerLink, Wiley Online Library y Cochrane Library, así como en guías internacionales. En los resultados se encontro como principales factores asociados el mal control glucémico, la hipertensión arterial, la obesidad, la dislipidemia, la edad avanzada y los inadecuados estilos vida. También se rescataron el control metabólico integral, las modificaciones de los estilos de vida, el tamizaje periódico de la función renal y el uso de fármacos nefroprotectores por sus beneficios clínicos. En conclusión, la prevención precoz y el abordaje multidisciplinario logran retrasar la progresión de la ERC y mejoran el pronóstico de los pacientes con DM2.